Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
gptkb:ketorolac
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
tablet
injection |
| gptkbp:brand |
gptkb:Toradol
|
| gptkbp:chemicalFormula |
C15H13NO3
|
| gptkbp:clinicalTrials |
Phase III
|
| gptkbp:commonName |
every 4 to 6 hours
10 mg to 30 mg |
| gptkbp:contraindication |
peptic ulcer disease
pregnancy bleeding disorders severe renal impairment hypersensitivity to NSAIDs |
| gptkbp:duration |
4 to 6 hours
|
| gptkbp:endOfLife |
5 to 6 hours
|
| gptkbp:firstAppearance |
1989
|
| gptkbp:formulation |
oral tablet
injectable solution |
| gptkbp:healthcare |
avoid alcohol
take with food do not exceed recommended dose consult doctor if pregnant or breastfeeding monitor for signs of bleeding |
| https://www.w3.org/2000/01/rdf-schema#label |
Toradol
|
| gptkbp:interactsWith |
alcohol
lithium anticoagulants other NSAIDs methotrexate |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mandates |
musculoskeletal pain
postoperative pain acute_pain |
| gptkbp:manufacturer |
gptkb:Roche
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
M01AB15
|
| gptkbp:route |
oral
intravenous intramuscular |
| gptkbp:sideEffect |
dizziness
headache nausea vomiting stomach pain |
| gptkbp:symptoms |
gastrointestinal bleeding
drowsiness renal failure nausea and vomiting |
| gptkbp:usedFor |
pain relief
|
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
255.27 g/mol
|